Others
SGG(SNBL Global Gateway)
Centered around our facility based in Washington State, USA, we are leveraging our long-cultivated CRO business and translational research (TR) business to develop the SNBL Global Gateway (SGG) project, which maximizes the use of our strong network with academia, investors, and professional companies in Japan and the US. This project aims to promote research, human resource development, business incubation, and information dissemination, with the goal of creating new business opportunities from a global perspective.
This project is being promoted in collaboration with the SBI Group, which has a wealth of experience in global investment business, focusing on the operation of business incubation facilities and fund management. By collaborating with multiple prestigious academic institutions in Japan and the US, we accelerate the social implementation of research results through the creation of university-originated venture companies. At the same time, we support the growth of Japanese companies aiming to enter the US market and American companies planning to enter the Japanese market, creating new business opportunities for both.
SNBL We will promote business expansion and growth by bringing together the experiences and strengths of both the Group and the SBI Group to maximize synergies between the business incubation business and the fund business.
Gemseki Investment
Our subsidiary, Gemseki Inc. Investment, actively provides funding through strategic investments in venture companies engaged in the research and development of pharmaceuticals and medical devices by forming a limited partnership with the company as a general partner. Additionally, our Gemseki business division strongly supports business development activities such as building partnerships and licensing activities, which are essential for the business advancement of venture companies and academia.
The main purpose of both projects is to support the growth of venture companies and academia, which have limited management resources such as funds and human resources, and to increase their value. Although they have not yet been released to the world, we aim to discover drug discovery and technology seeds from around the world with excellent potential as "gemstones," refine them, and sublimate them into "gems" in the form of valuable new drugs and medical devices. In order to promote the creation of innovative pharmaceuticals and medical devices and support their growth, theSNBL Group will establish a system to provide all kinds of support as a one-stop service and contribute to the advancement of global healthcare.
Development of Artificial Seed Production for Glass Eels
SNBL is working on the production and development of artificial seedlings of Japanese eels on Okinoerabu Island, Kagoshima Prefecture. Seedling refers to fry used in aquaculture. Eel farming (eel farming) uses white eels as seedlings, but the white eels used in the seedlings are only wild white eels harvested in estuary areas, and artificially produced white eels are not used.
Due to a decline in population, the Japanese eel was designated as an endangered species (category IB, species at high risk of extinction in the near future) on the IUCN Red List in 2014. Because of this rarity, glass eels are also called 'white diamonds,' leading to issues such as poaching.
If mass production through seed production is realized, it will enable the commercialization of fully farmed Japanese eels, contributing to market stabilization, prevention of overfishing of natural resources, and the preservation of Japan's food culture and marine resources. Additionally, it is expected to contribute to the local economy as a new industry in the region (Okinoerabu Island).
New Initiatives for Improving People's Health
SNBL has been promoting research by establishing a joint research chair at Juntendo University for three years since 2020 to promote the use of RWD (Real World Data).
RWD refers to the collective term for data obtained in the medical and health fields on a daily basis. With the advancement of digital technology, the digitization of clinical-related data has progressed, making it possible to collect large amounts of data, but the challenge is that the data is not standardized or structured.
We are actively promoting the support for commercialization utilizing digital technology and RWD, while effectively leveraging the network we have built over the years with pharmaceutical companies, medical institutions, and academia. By advancing the use of RWD, we believe we can contribute to improving the efficiency of the clinical development process for new drugs, curbing the increasing medical costs due to aging, enhancing the quality of health management and preventive services, and ultimately improving the health of many people and realizing a sustainable social security system.
